Chester County News and Community Website
PHOENIXVILLE, PA — PleoPharma Inc. secured a $6.5 million federal grant to advance a Phase 3 trial of its experimental treatment for cannabis withdrawal symptoms, providing three years of funding …
PleoPharma Wins $6.5 Million NIH Grant for Phase 3 Trial Read More PHOENIXVILLE, PA — PleoPharma has dosed the first patient in a Phase 3 clinical trial of an investigational treatment for cannabis withdrawal symptoms, advancing a drug candidate that could become …
PleoPharma Begins Phase 3 Trial for Cannabis Withdrawal Drug Read More PHOENIXVILLE, PA — PleoPharma, Inc. has closed a $36 million Series B financing round to accelerate development of PP-01, its lead investigational therapy for Cannabis Withdrawal in patients with Cannabis …
PleoPharma Secures $36 Million to Advance First Cannabis Withdrawal Treatment Read More PHOENIXVILLE, PA — PleoPharma, Inc. shared encouraging findings from its Phase 2b clinical trial of PP-01, a novel treatment for Cannabis Withdrawal Syndrome (CWS), during the 2025 annual meeting of …
PleoPharma Presents Promising Phase 2b Data on PP-01 for Cannabis Withdrawal Read More PHOENIXVILLE, PA — PleoPharma, Inc. has announced a significant intellectual property milestone with the issuance of its third U.S. patent, aimed at addressing sleep disturbances linked to cannabis withdrawal syndrome …
PleoPharma Secures Patent for Treating Sleep Disturbances in Cannabis Withdrawal Read More PHOENIXVILLE, PA — PleoPharma, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PP-01, the company’s lead investigational asset aimed at mitigating Cannabis …
FDA Grants Fast Track Designation to PleoPharma’s PP-01 for Cannabis Withdrawal Syndrome Read More